Chronic Stable Angina-Pipeline Insights, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 84619
Related Topics: FDA

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Chronic
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s, “ Chronic Stable Angina-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Chronic Stable Angina. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Chronic Stable Angina. DelveInsight’s Report also assesses the Chronic Stable Angina therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

• The report provides competitivepipeline landscape of Chronic Stable Angina

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Chronic Stable Angina pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Chronic Stable Angina and also provide company profiling

• The report also gives the information of dormant and discontinued pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time - 48-72 Hours

Table of Contents
for Chronic Stable Angina-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Chronic Stable Angina-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Chronic Stable Angina, 2017

• Number of Products under Development by Companies

• Comparative Analysis by Filed and Phase III Products, 2017

• Comparative Analysis Phase II Products, 2017

• Comparative Analysis Phase I and IND Filed Products, 2017

• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017

• Drug Candidates Profiles

• Chronic Stable Angina Assessment by Monotherapy Products

• Chronic Stable Angina Assessment by Combination Products

• Chronic Stable Angina Assessment by Route of Administration

• Chronic Stable Angina Assessment by Stage and Route of Administration

• Chronic Stable Angina Assessment by Molecule Type

• Chronic Stable Angina Assessment by Stage and Molecule Type

• Chronic Stable Angina Therapeutics – Discontinued Products

• Chronic Stable Angina Therapeutics – Dormant Products

• Products under Development by Companies, 2017

List Of Figures, Charts and Diagrams
in Chronic Stable Angina-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Chronic Stable Angina, 2017

• Filed and Phase III Products, 2017

• Phase II Products, 2017

• Phase I and IND Filed Products, 2017

• Discovery and Pre-Clinical Stage Products, 2017

• Chronic Stable Angina Assessment by Monotherapy Products

• Chronic Stable Angina Assessment by Combination Products

• Chronic Stable Angina Assessment by Route of Administration

• Chronic Stable Angina Assessment by Stage and Route of Administration

• Chronic Stable Angina Assessment by Molecule Type

• Chronic Stable Angina Assessment by Stage and Molecule Type

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

84619 | DIPR2017133

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Chronic Kidney Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! The Outlook for Wearable Health Tech in Managing Chronic Disease
IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
01 May 2016 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
01 Sep 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
20 Apr 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
27 May 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
20 Jan 2014 by FirstWord Pharma USD $6,371 (normally
USD $7,495)
More Info
SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
01 Jun 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...